Understanding GLP-1 signaling: A path to better therapiesUnderstanding GLP-1 signaling: A path to better therapies
About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions, according to a KFF Health Tracking poll. But many suffer from significant side effects including nausea or vomiting. And for diabetic patients who also have conditions such as cancer or Read More
Hypertension treatment linked to lower mortality for patients with metastatic breast cancerHypertension treatment linked to lower mortality for patients with metastatic breast cancer
Women with metastatic breast cancer often face multiple chronic conditions, and high blood pressure is among the most common. Nearly half of women in this study population had hypertension at diagnosis, with even higher rates among Black and Hispanic patients. Researchers have recently sought to understand whether more effective hypertension management could improve survival. Their work appears in Cancer Medicine.
There is more than one way for triple-negative breast cancer to become resistant to therapyThere is more than one way for triple-negative breast cancer to become resistant to therapy
About 50% of triple-negative breast cancer (TNBC) patients develop resistance to therapy. When resistance arises, tumors are more likely to come back after the original treatment, significantly reducing the chances of survival. Researchers at Baylor College of Medicine have discovered that there is more than one way TNBC can become immune to therapy.
Novel GLP-1 Pill Tops Oral Semaglutide for DiabetesNovel GLP-1 Pill Tops Oral Semaglutide for Diabetes
(MedPage Today) — An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ACHIEVE-3 trial showed. Among… (MedPage Today) — An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in Read More
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetesOral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had heart failure. The findings, published in JAMA Internal Medicine, come from a large randomized trial of nearly 9,650 adults who have Read More
A promising new drug for an invasive type of breast cancerA promising new drug for an invasive type of breast cancer
EPFL researchers have developed preclinical models for invasive lobular carcinoma and trialed a new drug. It slows tumor growth effectively by targeting specific features of the disease and opening the door to future clinical trials. The study is published in Cancer Research.
Science for living: Can using AI risk prediction in breast cancer screening improve early detection?Science for living: Can using AI risk prediction in breast cancer screening improve early detection?
Artificial intelligence is transforming medicine, but what does that mean for breast cancer screening? Researchers at UMass Chan Medical School are exploring how an AI-based tool might help identify women at higher risk for breast cancer and in doing so, detect cancers that standard mammograms might miss.
Study shows exercise during chemotherapy for breast cancer measurably improves quality of lifeStudy shows exercise during chemotherapy for breast cancer measurably improves quality of life
For many women with breast cancer, the very treatment that saves their lives can also bring fatigue, loss of muscle mass, emotional strain and other daunting obstacles. A new study shows that exercise during chemotherapy does more than rebuild strength—it measurably improves quality of life while treatment is underway, helping women feel better physically, emotionally and mentally during one of the most demanding chapters of care.
New GLP-1 pill helps patients lose up to 8% of body weight, trial showsNew GLP-1 pill helps patients lose up to 8% of body weight, trial shows
Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs A new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for an improved non-injection alternative to Wegovy and Mounjaro. The drug, called orforglipron Read More
New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trialNew GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial
A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 randomized controlled trial published in The Lancet. Additionally, participants taking orforglipron had significantly greater reductions in body weight than those taking oral Read More